Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.32 -0.08 (-0.85%) Market Cap: 2.84 Bil Enterprise Value: 2.52 Bil PE Ratio: 0 PB Ratio: 3.67 GF Score: 39/100

Iovance Biotherapeutics Inc at JMP Securities Hematology and Oncology Forum (Virtual) Transcript

Jun 18, 2020 / 06:20PM GMT
Release Date Price: $29.95 (+0.96%)
Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst

Well good afternoon, everyone. It's my pleasure to introduce Iovance Biotherapeutics, Maria Fardis, President and CEO. Maria, thanks for joining us here. And as I've been kind of starting off all the conversations with our cell therapy companies, we don't know exactly who's in the audience, whether they're familiar with Iovance, whether they're not, so would love to take maybe a couple of minutes, if you could give us an overview of Iovance.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Yes, absolutely. And thank you for the invitation, Reni. This is great to be here.

Iovance is a cell therapy company for administering a product called tumor-infiltrating lymphocytes, or TIL, for solid tumors. The original concept for the product came from National Cancer Institute, or NCI. We took a license in 2011. We have developed a product into now a commercial-ready product. The manufacturing process initially was around 6 to 7 weeks, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot